FDA approval: Sermorelin = pediatric GH deficiency only (branded version discontinued 2008)
Karl Nadolsky, an obesity-medicine specialist and AACE member, has stated: "Restricting access to GLP-1 receptor agonists through excessive step therapy contradicts the evidence base and delays treatment for a disease with cumulative cardiometabolic harm." The disconnect between this evidence and Kaiser's access barriers represents one of the more visible friction points in obesity pharmacotherapy coverage
If you want to lose fat without losing muscle, you need a plan that goes beyond the injection
These drugs havent been adequately studied in pregnant humans, but animal studies show potential risks, including: Embryo loss Fetal growth restriction Skeletal abnormalities Guidance for pregnancy planning: Stop Wegovy/Ozempic : At least 2 months before trying to conceive
Doctor Reviews &
J., Coskun, T., Thomas, M